Literature DB >> 32636504

FDA rejects NASH drug.

Asher Mullard.   

Abstract

Year:  2020        PMID： 32636504     DOI： 10.1038/d41573-020-00126-9

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  Synthetic human livers for modeling metabolic diseases.

Authors:  Edgar N Tafaleng; Michelle R Malizio; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 3.287

Review 2.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-10-26

3.  Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction.

Authors:  Yuhan Cao; Jingying Shi; Luyao Song; Junjiu Xu; Henglei Lu; Jianhua Sun; Jinjun Hou; Jing Chen; Wanying Wu; Likun Gong
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

4.  Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

Authors:  Moritz Helmstädter; Jurema Schmidt; Astrid Kaiser; Lilia Weizel; Ewgenij Proschak; Daniel Merk
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-29

5.  A New FXR Ligand Chemotype with Agonist/Antagonist Switch.

Authors:  Moritz Helmstädter; Jan Vietor; Jana Sommer; Simone Schierle; Sabine Willems; Astrid Kaiser; Jurema Schmidt; Daniel Merk
Journal:  ACS Med Chem Lett       Date:  2021-02-01       Impact factor: 4.345

Review 6.  Human biomimetic liver microphysiology systems in drug development and precision medicine.

Authors:  Albert Gough; Alejandro Soto-Gutierrez; Lawrence Vernetti; Mo R Ebrahimkhani; Andrew M Stern; D Lansing Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-17       Impact factor: 73.082

Review 7.  Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.

Authors:  Clarissa Berardo; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Mariapia Vairetti; Andrea Ferrigno
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

8.  Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

Authors:  Sina Ghandian; Rahul Thapa; Anurag Garikipati; Gina Barnes; Abigail Green-Saxena; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  JGH Open       Date:  2022-03-08

9.  Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis.

Authors:  Hsuan-Wu Hou; Christopher A Bishop; Jana Huckauf; Inge Broer; Susanne Klaus; Henrik Nausch; Johannes F Buyel
Journal:  Front Plant Sci       Date:  2022-09-29       Impact factor: 6.627
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.